GLP-1s for PCOS: what the evidence actually supports

What did @haileykatt actually say?

Let's be precise here. The video's audio transcript is, frankly, garbled, capturing what sounds like a side conversation about having children, nothing related to PCOS or GLP-1 therapy. The substantive claims come entirely from the written caption, which describes a frustrating PCOS history: failed trials of metformin, multiple types of birth control, various diets, and what sounds like ovulatory bleeding severe enough to function as a second period, plus menorrhagia and PMDD. She names Rybelsus (oral semaglutide) specifically and says her only regret is not starting sooner.

Because the actual spoken content doesn't address her medical claims, this fact-check focuses on what she wrote, since that's what 12,100 viewers are reading.

Does the science back this up?

Mostly, yes, with important caveats about what GLP-1s can and cannot do for PCOS. The evidence is promising but not definitive. GLP-1 receptor agonists do appear to improve hormonal and menstrual irregularities in women with PCOS, likely through multiple mechanisms including insulin sensitization and modest weight reduction.

A 2023 randomized controlled trial by Jensterle et al. published in Diabetes, Obesity and Metabolism found that semaglutide significantly reduced androgen levels and improved menstrual regularity in overweight women with PCOS compared to placebo. An earlier meta-analysis by Liu et al. (2019, Reproductive Biology and Endocrinology) pooled data on liraglutide and found improvements in menstrual frequency, testosterone, and fasting insulin. The biological rationale is solid: hyperinsulinemia drives androgen overproduction in many PCOS phenotypes, and anything that blunts insulin resistance can downstream reduce symptoms like heavy or irregular bleeding.

That said, most trials are small, short-duration, and focused on overweight or obese patients. Whether lean PCOS patients get the same benefit is genuinely unclear. Rybelsus (oral semaglutide) specifically has less PCOS-focused trial data than injectable semaglutide.

What did they get wrong (or right)?

She got the frustration right. Metformin is first-line insulin sensitization for PCOS and it works for some people, but a meaningful subset of patients don't tolerate it or don't respond adequately. Birth control manages symptoms but doesn't address the underlying metabolic dysfunction. The caption reflects a real clinical gap that GLP-1s may genuinely help fill for certain patients.

Where she's on thinner ice: the implicit claim that GLP-1s fixed her ovulation-related bleeding and menorrhagia. Heavy menstrual bleeding has multiple causes, including fibroids, adenomyosis, and coagulation disorders, that GLP-1s don't touch. Crediting a single drug for resolving complex menstrual pathology without ruling out other contributors is a logical leap. It may be accurate for her specific case, but framing it as broadly applicable is where anecdote starts doing work that evidence hasn't earned yet.

She doesn't overclaim a cure. She says she wishes she started sooner. That's restrained, honestly, for a TikTok health post.

What should you actually know?

If you have PCOS and your current regimen isn't working, GLP-1 receptor agonists are a legitimate conversation to have with a provider, not a guaranteed fix. The evidence supports trialing them, particularly if insulin resistance is part of your presentation. But a few things matter:

• GLP-1s are not FDA-approved specifically for PCOS. Use in this context is off-label, which isn't disqualifying, but it means the evidence base is thinner than for type 2 diabetes or obesity indications.
• Rybelsus (oral semaglutide) has lower and more variable bioavailability than injectable semaglutide. Results may differ.
• Heavy menstrual bleeding should be investigated independently. Don't assume a GLP-1 will fix it without a proper workup.
• Weight loss, if it occurs, likely accounts for some hormonal improvement. The drug's direct effect on PCOS pathophysiology, separate from weight, is still being studied (Salamun et al., 2018, Endocrine Connections).

Her experience is valid. It shouldn't be your treatment plan.